

"Sine Phenomenon" in Dermatology

Ümit Türsen,* MD, Belma Türsen,** MD

Address: *Mersin University, Medical Faculty, Dermatology Department, **Mersin Hospital, Dermatology Department, Mersin, Turkey.

E-mail: utursen@mersin.edu.tr

* Corresponding Author: Mersin University, Medical Faculty, Dermatology Department, 33079-Mersin

Published:

J Turk Acad Dermatol 2013; 7 (2): 1372r1.

This article is available from: <http://www.jtad.org/2013/2/jtad1372r1.pdf>

Key Words: Sine, phenomenon, dermatology.

Abstract

Background: In dermatology, the term sine is often used in regard to any sign, symptom or finding whose absence would very likely mean uncommon variant of the target disease or condition. Sine phenomenon can be seen in different dermatological diseases such as scleroderma, polymorphic light eruption, dermatomyositis, pellagra, zona, psoriasis, necrobiosis lipoidica, lupus erythematosus, seborrheic keratosis, eccrine hidradenitis and acne fulminans.

Introduction

"Sine" means lacking or without especially in Latin phrases [1]. In dermatology, the term sine is often used in regard to any sign, symptom or finding whose absence would very likely mean uncommon variant of the target disease or condition [2]. The absence of such a sign, symptom or finding would thereby have very high sensitivity, and rarely miss the condition, so a negative result should be reassuring for sine phenomenon in dermatology. Sine phenomenon can be seen in different dermatological disease such as scleroderma, polymorphic light eruption, dermatomyositis, pellagra, zona, psoriasis, necrobiosis lipoidica, lupus erythematosus, seborrheic keratosis, eccrine hidradenitis and acne fulminans [3].

Dermatomyositis Sine Myositis

This is a historic term, which has now been replaced by the term amyopathic dermatomyositis, which is a variant of dermatomyositis. This terminology is used when there is a biopsy-proven hallmark skin lesion of cutaneous dermatomyositis without any presence of muscle involvement for 6 months or longer [4]. There should be neither clinical evidence of proximal muscle involvement nor any abnormalities in serum muscle enzymes. Other investigations for muscle involvement like electromyogram and muscle biopsy should be normal if done [5]. Sun *et al.* observed that the prevalence of interstitial lung disease in Chinese

amyopathic dermatomyositis patients is strikingly high, and acute/subacute interstitial pneumonia is a major cause of death in amyopathic dermatomyositis patients. They recommend that laboratory findings combined with high-resolution computed tomography examination and pulmonary function tests can provide valuable predictive information of interstitial lung disease or acute/subacute interstitial pneumonia in amyopathic dermatomyositis patients [6]. Treatment with immunosuppressive drugs for 2 months or more within 6 months of onset of cutaneous lesions and use of drugs like hydroxyurea, and statins, which are capable of producing dermatomyositis like cutaneous changes, are exclusion criteria for amyopathic dermatomyositis [5]. There have been reports of typical skin lesions of dermatomyositis occurring without or with minimal evidence of myositis, the cases being labelled variously as dermatomyositis sine myositis, and amyopathic dermatomyositis.

However, the original classification of dermatomyositis by Bohan and Peter did not include such an entity [7]. Euwer and Sontheimer have divided amyopathic dermatomyositis into 3 types: Type I: Pure amyopathic dermatomyositis patients who have only skin disease. Type II: Patients with skin disease who have subjective myalgias and weakness but not laboratory evidence of muscle disease. Type III: Patients with no muscle weakness clinically but who have evidence of abnormal laboratory tests at some time during their course [8]. Dermatomyositis sine myositis can occur as all types.

Systemic Sclerosis Sine Scleroderma

Scleroderma or systemic sclerosis is characterized by the presence of thickening and induration of the skin. Major organ involvement as part of systemic sclerosis without the characteristic skin changes of scleroderma, defined as systemic sclerosis sine scleroderma, was first described in 1954. The terminology "systemic sclerosis sine scleroderma" refers to those patients of systemic sclerosis who do not show cutaneous features of systemic sclerosis but exhibit vascular (like *Raynaud's* phenomenon), immunologic findings and internal organ involvement as seen in systemic sclerosis. These comprise of nearly 1% of all systemic sclerosis patients [9]. *Pauling et al.* observed a case of pulmonary artery hypertension as the presenting feature of systemic sclerosis sine scleroderma. They concluded this case highlights the importance of close monitoring of patients who present with *Raynaud's* phenomenon and a strongly positive nucleolar ANA pattern, for further organ involvement such as pulmonary artery hypertension that can now be effectively treated if detected early enough. In addition, the presence of abnormal nail-fold capillaries at presentation could be another indicator of future risk. A strong case can be made for such patients having annual pulmonary function tests and echocardiography to estimate pulmonary artery pressures as is currently recommended for patients with scleroderma [10]. *Korzets et al.* observed a case of scleroderma renal crisis (scleroderma renal crisis sine scleroderma sine hypertension) [11]. Systemic sclerosis sine scleroderma should be included in the spectrum of systemic sclerosis with limited cutaneous involvement and should not be considered a distinct or separate disorder.

Linear Melorheostotic Scleroderma with Hypertrichosis Sine Melorheostosis

Linear melorheostotic scleroderma (LMS) is a condition, which is characterized by linear scleroderma like changes with cortical hyperostosis of the bones, exhibiting a dripping of burning candle-like appearance on radiography [12, 13]. However, the term LMS with hypertrichosis sine melorheostosis is used when the scleroderma like changes is seen with an increased growth of hair, but the characteristic bone changes are absent. Melorheostosis is a rare sclerosing dysplasia wherein the affected bone demonstrates a cortical or endosteal hyperostosis, characterized roentgenographically. Since its original description in 1922 by *Leri & Joanny*, more than 250 cases have been reported. In 1936, *Dillehunt & Chuinard* described a case in which a lesion defined as "linear scleroderma" was associated with melorheostosis. In one study, scleroderma-like skin changes and melorheostosis were reported to coexist in approximately 5% of 131 cases. In 1972, proposing a more appropriate term "linear melorheostotic scleroderma", *Wagers et al.* described the clinical and histological features that distinguish the cutaneous changes of LMS from those of linear scleroderma [14, 15]. The pathogenesis of LMS is unknown. *Wagers et al.* proposed the possibility that the skin lesions were similar to the bone lesions in terms of the pathomechanism. As for its pathogenesis, inflammation and vascular abnormality have been proposed [14]. *Muller & Henderson* postulated that the sclerosing changes in the skin of LMS should be derived from a primary mesenchymal defect that occasionally spills over into the skeletal tissues. However, many others favour the notion

of a common developmental error both in the cutaneous and skeletal lesions. *Fimiani et al.* suggested the possibility that LMS is an integral part of a hamartoma that may affect one or more tissues, which was supported by the coexistence of hypertrichosis with LMS, as noted in the present case. Hypertrichosis in LMS lesions is infrequent, but has been reported in five cases. There are three possible explanations for LMS that are not accompanied by bone alteration. First, there may be a difference in the onset of the pathogenic changes between the skin and bone. In fact, in a few previous cases melorheostosis became evident only several years after the appearance of the skin lesion. Secondly, it is possible that some cases of LMS without melorheostosis have been diagnosed as linear scleroderma. Thirdly, available instruments may overlook slight bone alterations in the early stage of melorheostosis. Although bone scintigraphy is often available to detect slight bone alterations, the parents of the present patient refused further study. No prophylaxis or therapy is effective to prevent the progression of melorheostosis [12, 13, 14, 15].

Psoriatic Arthritis Sine Psoriasis

This terminology refers to those patients who present with symptoms and signs of psoriatic arthritis but without any cutaneous psoriatic lesions, however, have a history of psoriasis in a first or second degree relative [16, 17]. In about 20% of patients with psoriatic arthritis the rheumatological manifestations precede the onset of the cutaneous lesions. If there is a family history of psoriasis these patients are diagnosed as having psoriatic arthritis sine psoriasis. In the past, they were also classified among patients with undifferentiated spondyloarthritis. The clinical spectrum of psoriatic arthritis sine psoriasis is wide and identified by dactylitis and/or distal interphalangeal arthritis, HLA-Cw6, and a family history of psoriasis. The Classification of Psoriatic Arthritis (CASPAR) criteria of psoriatic arthritis include psoriatic arthritis sine psoriasis [17]. *Scarpa et al.* think that a subset of patients with psoriatic arthritis "sine psoriasis" is identified by the occurrence of a spondyloarthropathy with dactylitis and/or distal interphalangeal arthritis, presence of HLA-Cw6, and familial psoriasis in first or second-degree relatives [16].

Polymorphic Light Eruption Sine Eruption

Polymorphic light eruption sine eruption is a variant of polymorphic light eruption (PLE), which is characterized by an intense pruritus on the sun-exposed areas without the development of any cutaneous lesions. The pruritus usually develops by 45 minutes to a day, and subsides by 1 to 5 days. *Dower and Hawk* describe seven patients, four female and three male, who developed intense pruritus on sun-exposed skin without visible change. The clinical features resembled those of polymorphic light eruption without rash. Four patients also occasionally developed typical polymorphic light eruption upon sun exposure, but sun-induced pruritus alone occurred most frequently. No patient was taking any drug therapy. One patient developed similar pruritus following solar simulated irradiation, and one following PUVA therapy. All other laboratory investigations were negative. Treatment with low dose UVB phototherapy or PUVA therapy was effective. The condition, which they have called polymorphic light eruption sine eruption (PLESE), appears

to be a variant of polymorphic light eruption [18, 19]. Commens also showed a case of polymorphic light eruption sine eruptione and brachioradial pruritus [19].

Pellagra Sine Pellagra

Pellagra sine pellagra refers to those patients who manifest clinical features of pellagra in the absence of the classical cutaneous photosensitive dermatosis like Casal's necklace, gauntlet of pellagra. This is seen in those patients of pellagra who do not go outdoors (thus avoiding photoexposure) and also among patients with riboflavin deficiency, rather than niacin deficiency [20]. *Ishii N et al.* showed that although patients with pellagra had presented with various mental, neurological and gastrointestinal symptoms, the diagnosis of pellagra had not been established clinically because, in the majority, there were no skin lesions. It is emphasised that whenever chronic alcoholics exhibit certain mental, neurological or gastrointestinal symptoms, one should strongly suspect pellagra sine pelle agra even in the absence of skin lesions [21].

Zoster Sine Herpete (Syn: Zoster sine eruptione)

The term zoster sine herpete was coined by *Weber* in 1916 to describe herpes zoster without the classic rash. Herpes zoster is characterized by the occurrence of grouped vesicles on an erythematous base in a dermatomal pattern. The onset of the eruptions is preceded by sharp pain 2 - 4 days prior. However, in some patients, this pain is not followed by the occurrence of any cutaneous lesions. This is known as zoster sine herpete [22, 23, 24]. *Jaworsky* reported a case of metastatic transitional cell carcinoma mimicking zoster sine herpete. They concluded that dermatomal pain could occur with neural metastases as well [22]. *Vena* reported a case of zoster "almost" sine herpete: diagnostic utility of real time-polymerase chain reaction. This report describes the case of a female patient, presenting with intercostal pain associated with a single papulo-vesicular lesion localized within the same area [24]. *Yaguchi* reported a case of zoster sine herpete presenting with dysphagia diagnosed by polymerase chain reaction analysis of VZV DNA in auricular skin exudates [25]. *Hon C et al.* indicated a case of ophthalmic zoster sine herpete presenting as oculomotor palsy after marrow transplantation for acute myeloid leukemia [26]. Herpes zoster sine herpete can be also present as hyphema, trigeminal neuralgia, disciform keratitis, encephalomyelitis, facial palsy, uveitis, cranial and upper cervical nerves involvement, iridocyclitis, lateral sinus thrombosis, truncal sensory deficit, retinal periphlebitis and thoracic motor paralysis [27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39].

Malignant Acanthosis Nigricans Sine Malignancy

Malignant acanthosis nigricans is very similar to acanthosis nigricans in clinical appearance, but is usually sudden in onset, progressive, darker and extensive. It also involves the mucosal surfaces and palms. Malignant acanthosis nigricans may occur simultaneously, precede or follow occurrence of an internal malignancy and subsides with removal of the malignancy. The term malignant acanthosis nigricans sine malignancy is used when the patient presents with malignant acanthosis nigricans

and extensive evaluation and investigations fail to reveal the presence of any malignancy [40].

Acne Fulminans Sine Fulminans

Acne fulminans was first described in 1959 and it is a rare form of acne, characterized by an acute onset of cystic acne, which tends to rupture leading to ulcerations, along with systemic manifestations like fever, malaise, myalgia, nausea, polyarthropathy, anorexia and osteolytic lesions [41, 42, 43]. Acne fulminans sine fulminans is a variant, which presents with cutaneous lesions, similar to acne fulminans but with minimum or nil systemic features [43]. Response to traditional acne therapies is poor. It is characteristically of sudden onset, most common in adolescent males and although response to isotretinoin is poor, patients usually respond to oral corticosteroids [44]. In a number of cases a familial association has been described. The aetiology of acne fulminans is not clearly established. In view of the familial associations, genetic susceptibility is likely. There is evidence of an altered immunological reaction to *Propionibacterium acnes* in some patients, with previous demonstration of both type III and IV hypersensitivity to this organism. Another theory is that altered neutrophil function may result in severe acne flares. P. acnes destruction is thought to result in mediator release, inducing neutrophil chemotaxis, which may be responsible for the early flares seen on treatment with isotretinoin [45, 46]. *Thomson et al.* feel that it is important to identify patients of the acne fulminans 'sine fulminans' group so that modifications in treatment may be implemented [43]. These patients all showed a poor response to isotretinoin therapy, with resultant acne flare even at a modest dose. All patients developed scarring as a result of their acne lesions and the emphasis should therefore be on prevention of the severe flare. As has previously been identified, macrocomedones are a cause of flares in acne treated with isotretinoin. All but one of these patients had multiple macrocomedones and it is important that all acne patients are examined for these and treated with gentle cautery if necessary, allowing areas to heal (1-2 weeks) prior to commencing isotretinoin. In patients with macrocomedones, low dose isotretinoin (≤ 0.2 mg/kg/day) should be used. In patients who flare on low dose, the isotretinoin should be reduced further or stopped and the addition of a reducing dose of corticosteroids (0.5-1.0 mg/kg/day) should be considered. Patients who already show an acne fulminans 'sine fulminans' picture, should be treated in a similar fashion, with macrocomedones treated initially if present. Patients receiving isotretinoin should have this stopped or reduced to 0.2 mg/kg/day until the worst of the ulcerative fulminans lesions have resolved. Prednisolone should be given at a dose of 0.5-1.0 mg/kg/day with duration according to disease severity. This should be reduced gradually over weeks or months according to patient response, increasing the dose or reinstating prednisolone if disease flares occur. Patients not having received prior isotretinoin can be started on a low dose of this after 2 weeks treatment with prednisolone. Long-term low dose isotretinoin is frequently required, sometimes up to 2 years if necessary. In summary, authors have classified a group of patients with severe acne of sudden onset, as having acne fulminans 'sine fulminans' [41, 42, 43, 44, 45, 46, 47, 48]. Severity of disease is similar to that seen in acne fulminans but with no systemic features. This group sho-

uld be identified, as modification of acne therapy is required.

Eruptive Seborrheic Keratosis Sine Malignancy

The sudden eruptive onset or sudden increase in the size of existing seborrheic keratosis, often referred to as the *Leser-Trélat* sign, is associated with malignancy, especially adenocarcinomas of the gastro-intestinal system. Eruptive seborrheic keratosis sine malignancy or the false *Leser-Trélat* refers to the condition of eruptive seborrheic keratosis where extensive investigations fail to reveal the presence of any malignancy. *Rampen et al.* think that the sign of *Leser-Trélat* is usually regarded as a reliable cutaneous marker of internal malignancy. They have reviewed the literature and conclude that the evidence for a causal relation between eruptive seborrheic keratoses and cancer is meager [49]. Eruptive seborrheic keratosis could be also presented with neurofibromatosis, erythrodermic pityriasis rubra pilaris, eczema, human immunodeficiency virus infection, pemphigus foliaceus and erythrodermic psoriasis [50, 51, 52, 53, 54, 55].

Pruritus Sine Materia

The terminology pruritus sine materia is used to describe those conditions of pruritus, which occur on non-inflamed, non-diseased skin and includes pruritus secondary to systemic, neurological, psychosomatic or psychiatric origin and even pruritus that occurs in elderly people. Pruritus can be divided into several categories: pruritoceptive, neurogenic, neuropathic, and psychogenic. Neuropathic itch is caused by lesions of afferent neural pathways. Psychogenic itch is secondary to primary psychiatric disorders. Both of these types of pruritus present with no evidence of primary cutaneous lesions. The presentation of both conditions can be confusing and patients with no primary cutaneous lesions can be prematurely diagnosed as having a psychiatric disorder. Treatment of neuropathic and psychogenic pruritus can be divided into pharmacologic and nonpharmacologic therapies. Medications used include topical capsaicin and anesthetic agents, antiepileptic agents, tricyclic antidepressants, selective serotonin reuptake inhibitors, and atypical antipsychotic agents. Nonpharmacologic therapies such as psychotherapy and hypnosis have been beneficial [56, 57].

Afifi et al described the nature and the frequency of systemic diseases responsible for the pruritus sine materia. Value of this sign as a marker of malignancy. Prospective study undertaken over five years and 95 patients included. In 38 cases (40%), a systemic cause was found. The main conditions were: toxocariasis (8 cases), hematologic diseases (7 cases), chronic renal failure (6 cases), hypothyroidism (5 cases) and iron deficiency (5 cases). A neoplasm was found in eight cases (8,42%): seven hematologic malignancy (3 myeloma, 2 Hodgkin's diseases, 2 myeloproliferative syndromes) and one solid cancer (pulmonary adenocarcinoma). They concluded a systemic aetiology was observed in 38 cases (40%). The toxocariasis an underestimated disease comes at the first place. The pruritus sine materia can hide an hematologic malignancy [57]. *Darsow et al.* reported a case of pruritus circumscriptus sine materia: a sequel of postzoster neuralgia [58].

Lupus Sine Lupo

The cutaneous lesions of lupus erythematosus are categorized into specific and non-specific on the basis of the *Gilliam* classification. The term lupus sine lupo is used when the patient fails to have any specific lesions of lupus erythematosus [59, 60].

Eccrine Hidradenitis Sine Neutrophils

Neutrophilic eccrine hidradenitis presents as tender erythematous papules and plaques and is often associated with chemotherapy for acute myeloid leukemia. Eccrine hidradenitis, often referred to as neutrophilic eccrine hidradenitis, is a condition, characterized histopathologically with eccrine degeneration and surrounding neutrophilic infiltrate often described post chemotherapy or associated with infectious agents. In eccrine hidradenitis sine neutrophils, the surrounding neutrophil infiltrate is deficient. *Yeh et al* presented a case of hidradenitis occurring in a patient after chemotherapy for acute myeloid leukemia in the setting of profound neutropenia. Neutrophilic eccrine hidradenitis is postulated to be due to toxic injury to the sweat glands followed by neutrophilic inflammation. Alternatively, some hypothesize that neutrophilic eccrine hidradenitis represents a primary neutrophilic process. Neutrophil-poor variants of hidradenitis, both infectious and due to drug toxicity, should be considered diagnostically in neutropenic patients [61].

Necrobiosis Lipoidica Sine Diabetes

Necrobiosis lipoidica is closely associated with diabetes with nearly 70% of the patients exhibiting diabetes. The term necrobiosis lipoidica sine diabetes is used to describe those patients of necrobiosis lipoidica who do not have diabetes. However, necrobiosis lipoidica can precede the onset of diabetes in nearly 15% of the patients [62].

Keratosis Follicularis Sine Dyskeratosis

Diasio reported a patient was seen in consultation in the clinic with an eruption that appeared to fulfill clinically all the diagnostic criteria of keratosis follicularis (Darier disease). However, further study of the case, including microscopic examination of a biopsy specimen, proved his tentative diagnosis to be incorrect. Since he has not been able to find a description of a similar case in the literature and since this hitherto unknown dermatosis mimics not only Darier's disease but also other follicular disorders, he was tempted to report his case [63].

References

1. http://en.wikipedia.org/wiki/List_of_Latin_phrases:_S
2. Denton CP, Black CM. Scleroderma (Systemic Sclerosis). In: Fitzpatrick's Dermatology In General Medicine. Wolff K, Goldsmith LA, Katz SI, Gicherst BA, Paller AS, Leffell DJ, eds. 7th ed. New York: Mc Graw Hill; 2008, 1553-1562.

3. Nayak SU, Sheno SD. "Sines" of dermatology. *Indian J Dermatol Venereol Leprol* 2012; 78: 490-491. PMID: 22772623
4. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? *J Am Acad Dermatol* 2002; 46: 626-636. PMID: 11907524
5. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. *J Invest Dermatol* 1993; 100: 124S-127S.
6. Sun Y, Liu Y, Yan B, Shi G. Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients. *Rheumatol Int* 2012 Nov 10. PMID: 23143553
7. Bohan A, Peter JB. Polymyositis and dermatomyositis. *N Engl J Med* 1975; 292: 344-347. PMID: 109083.
8. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). *J Am Acad Dermatol* 1991; 24: 959-966. PMID: 1869684
9. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. *Arthritis Rheum* 2000; 43: 444-451. PMID: 10693887
10. Pauling JD, Gunawardena H, Coghlan JG, Easaw J, Suntharalingam J, McHugh NJ. Pulmonary artery hypertension as the presenting feature of systemic sclerosis sine scleroderma. *Rheumatology (Oxford)* 2008; 47: 1431-1432. PMID: 18603658
11. Korzets Z, Schneider M, Savin H, Ben-Chetrit S, Bernheim J, Shitrit P, Bernheim J. Intriguing presentation of scleroderma renal crisis (scleroderma renal crisis sine scleroderma sine hypertension). *Nephrol Dial Transplant* 1998; 13: 2953-2956. PMID: 9829513
12. Fimiani M, Rubegni P, De Aloe G, Andreassi L. Linear melorheostotic scleroderma with hypertrichosis sine melorheostosis. *Br J Dermatol* 1999; 141: 771-772. PMID: 10583151
13. Nakajima I, Okuyama R, Tagami H, Aiba S, Kuramoto Y. Linear melorheostotic scleroderma without melorheostosis. *Acta Derm Venereol* 2006; 86: 163-164. PMID: 16648925
14. Wagers LT, Young AW Jr, Ryan SF. Linear melorheostotic scleroderma. *Br J Dermatol* 1972; 86: 297-301. PMID: 5018681
15. Miyachi Y, Horio T, Yamada A, Ueo T. Linear melorheostotic scleroderma with hypertrichosis. *Arch Dermatol* 1979; 115: 1233-1234. PMID: 507873
16. Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M, Ayala F, D'Arienzo A, Oriente P. Clinical and genetic aspects of psoriatic arthritis "sine psoriasis" *J Rheumatol* 2003; 30: 2638-2640. PMID: 14719207
17. Olivieri I, Padula A, D'Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. *J Rheumatol Suppl* 2009; 83: 28-29. PMID: 19661535
18. Dover JS, Hawk JL. Polymorphic light eruption sine eruption. *Br J Dermatol* 1988; 118: 73-76. PMID: 3342178
19. Commens C. Polymorphic light eruption sine eruption and brachioradial pruritus. *Br J Dermatol* 1988; 119: 554. PMID: 3191025
20. Patnaik R, Chowdary TN, Sesikeran B, Satyanath RV, Kumar PU. Nutrition and the skin. In: IADVL Textbook of Dermatology. Valia RG, Valia AR, eds. 3rd ed. Mumbai: Bhalani Publishing House; 2008, 1273-1277.
21. Ishii N, Nishihara Y. Pellagra among chronic alcoholics: clinical and pathological study of 20 necropsy cases. *J Neurol Neurosurg Psychiatry* 1981; 44: 209-215. PMID: 7229643
22. Jaworsky C, Bergfeld WF Metastatic Transitional Cell Carcinoma Mimicking Zoster Sine Herpete. *Arch Dermatol* 1986; 122: 1357-1358. PMID: 3789766
23. Blumenthal DT, Shacham-Shmueli E, Bokstein F, Schmid DS, Cohrs RJ, Nagel MA, Mahalingam R, Gildden D. Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. *Neurology* 2011; 76: 484-485. PMID: 21282595
24. Vena GA, Apruzzi D, Vestita M, Calvario A, Foti C, Cassano N. Zoster "almost" sine herpete: diagnostic utility of real time-polymerase chain reaction. *New Microbiol* 2010; 33: 409-410. PMID: 21213602
25. Yaguchi H, Hisatomi M, Sekine T, Matsui K, Nagatomo M, Inoue K. Case of zoster sine herpete presenting with dysphagia diagnosed by PCR analysis of VZV DNA in auricular skin exudates. *Rinsho Shinkeigaku* 2006; 46: 668-670. PMID: 17260814
26. Hon C, Au WY, Cheng VC. Ophthalmic zoster sine herpete presenting as oculomotor palsy after marrow transplantation for acute myeloid leukemia. *Haematologica* 2005; 90: EIM04. PMID: 16464763
27. Easton HG. Zoster sine herpete causing acute trigeminal neuralgia. *Lancet* 1970; 2: 1065-1066. PMID: 4098355
28. Silverstein BE, Chandler D, Neger R, Margolis TP. Disciform keratitis: a case of herpes zoster sine herpete. *Am J Ophthalmol* 1997; 123: 254-255. PMID: 9186133
29. Mancardi GL, Melioli G, Traverso F, Tabaton M, Farinelli M, Terragna A. Zoster sine herpete causing encephalomyelitis. *Ital J Neurol Sci* 1987; 8: 67-70. PMID: 3032844
30. Furuta Y, Ohtani F, Mesuda Y, Fukuda S, Inuyama Y. Early diagnosis of zoster sine herpete and antiviral therapy for the treatment of facial palsy. *Neurology* 2000; 55: 708-710. PMID: 10980741
31. Akpek EK, Gottsch JD. Herpes zoster sine herpete presenting with hyphema. *Ocul Immunol Inflamm* 2000; 8: 115-118. PMID: 10980684
32. Goon P, Wright M, Fink C. Ophthalmic zoster sine herpete. *J R Soc Med* 2000; 93: 191-192. PMID: 10844885
33. Kashiwase M, Sakai J, Usui M. Uveitis associated with zoster sine herpete. Diagnosis and clinical findings. *Nihon Ganka Gakkai Zasshi* 2000; 104: 97-102. PMID: 10714158

34. Funakawa I, Terao A, Koga M. A case of zoster sine herpette with involvement of the unilateral IX, X and XI cranial and upper cervical nerves. *Rinsho Shinkeigaku* 1999; 39: 958-960. PMID: 10614162
35. Schwab IR. Herpes zoster sine herpette. A potential cause of iridoplegic granulomatous iridocyclitis. *Ophthalmology* 1997; 104: 1421-1425. PMID: 9307636
36. Chan J, Bergstrom RT, Lanza DC, Oas JG. Lateral sinus thrombosis associated with zoster sine herpette. *Am J Otolaryngol* 2004; 25: 357-360. PMID: 15334402
37. Yamada S, Atsuta N, Tokunaga S, Motegi Y. Ipsilateral truncal sensory deficit in a patient with ophthalmic zoster sine herpette. *Neurology* 2003; 60: 1049-1050. PMID: 12654984
38. Noda Y, Nakazawa M, Takahashi D, Tsuruya T, Saito M, Sekine M. Retinal periphlebitis as zoster sine herpette. *Arch Ophthalmol* 2001; 119: 1550-1552. PMID: 11594964
39. Schuchmann JA, McAllister RK, Armstrong CS, Puana R. Zoster sine herpette with thoracic motor paralysis temporally associated with thoracic epidural steroid injection. *Am J Phys Med Rehabil* 2008; 87: 853-858. PMID: 18806512
40. Jeevankumar B, Thappa BM, Karthikeyan K. Malignant acanthosis nigricans sine malignancy. *Indian J Dermatol* 2003; 48: 176-178.
41. Burke BM & Cunliffe WJ. The assessment of acne vulgaris – The Leeds technique. *Br J Dermatol* 1984; 111: 83-92. PMID: 6234917
42. Burns RE & Colville JM. Acne conglobata with septicaemia. *Arch Dermatol* 1959; 79: 361, 3.
43. Thomson KF, Cunliffe WJ. Acne fulminans 'sine fulminans'. *Clin Exp Dermatol* 2000; 25: 299-301. PMID: 10971490
44. Karvonen SL. Acne fulminans: report of clinical findings and treatment of 24 patients. *J Am Acad Dermatol* 1993; 28: 572-579. PMID: 7681856
45. Jong Wong SAI, Pritchard MH, Holt PJA. Familial acne fulminans. *Clin Exp Dermatol* 1992; 17: 351-3. PMID: 1458644
46. Williamson DM, Cunliffe WJ, Gatecliff M et al. Acute ulcerative acne conglobata (acne fulminans) with erythema nodosum. *Clin Exp Dermatol* 1977; 2: 351. PMID: 146578
47. Karnoven SL, Rasanen L, Cunliffe WJ et al. Delayed hypersensitivity to Propionibacterium acnes in patients with severe nodular acne and acne fulminans. *Dermatology* 1994; 189: 344-349. PMID: 7873817
48. Perkins W, Crockett KV, Hodgkins MB et al. The effect of treatment with 13-cis-retinoid acid on the metabolic burst of peripheral blood neutrophils from patients with acne. *Br J Dermatol* 1991; 124: 429-432. PMID: 1828174
49. Rampen HJ, Schwengle LE. The sign of Leser-Trélat: does it exist? *J Am Acad Dermatol* 1989; 21: 50-55. PMID: 2526165
50. Takci Z, Simsek GG, Tekin O. A segmental neurofibromatosis case with eruptive seborrheic keratoses. *J Pak Med Assoc* 2012; 62: 960-962. PMID: 23139984
51. Gleeson CM, Chan I, Griffiths WA, Bunker CB. Eruptive seborrheic keratoses associated with erythrodermic pityriasis rubra pilaris. *J Eur Acad Dermatol Venereol* 2009; 23: 217-218. PMID: 18482315
52. Monteagudo B, Alvarez-Alvarez C, López-Mouriño VM. Eruptive seborrheic keratoses triggered by eczema. *Actas Dermosifiliogr* 2005; 96: 130. PMID: 16476353
53. Inamadar AC, Palit A. Eruptive seborrheic keratosis in human immunodeficiency virus infection: a coincidence or 'the sign of Leser-Trélat'? *Br J Dermatol* 2003; 149: 435-436. PMID: 12932267
54. Bagheri MM, Alagheband M, Memar OM, Eiler DB. Pemphigus foliaceus presenting as eruptive seborrheic keratosis and responding to oral gold treatment. *J Drugs Dermatol* 2002; 1: 333-334. PMID: 12851996
55. Flugman SL, McClain SA, Clark RA. Transient eruptive seborrheic keratoses associated with erythrodermic psoriasis and erythrodermic drug eruption: report of two cases. *J Am Acad Dermatol* 2001; 45: 212-214. PMID: 11712062
56. Tuerk MJ, Koo J. A practical review and update on the management of pruritus sine materia. *Cutis* 2008; 82: 187-194. PMID: 18856158
57. Afifi Y, Aubin F, Puzenat E, Degouy A, Aubrion D, Hassam B, Humbert P. Pruritus sine materia: a prospective study of 95 patients. *Rev Med Interne* 2004; 25: 490-493. PMID: 15219366
58. Darsow U, Lorenz J, Bromm B, Ring J. Pruritus circumscriptus sine materia: a sequel of postzoster neuralgia. Evaluation by quantitative psychophysical examination and laser-evoked potentials. *Acta Derm Venereol* 1996; 76: 45-47. PMID: 8721492
59. Okuda M, Fukuoka Y. Clinical findings of lupus sine lupo, with special reference to septicemia and other similar refractory infections. *Naika* 1970; 25: 748-752. PMID: 5423426
60. Lafaix C, Rey M, Boisson ME. Sine lupo lupus erythematosus disseminatus revealed by pericarditis (apropos of a case observed at Dakar). *Bull Soc Med Afr Noire Lang Fr* 1968; 13: 623-627. PMID: 5729004
61. Yeh I, George E, Fleckman P. Eccrine hidradenitis sine neutrophils: a toxic response to chemotherapy. *J Cutan Pathol* 2011; 38: 905-910. PMID: 21955315
62. Götz H. Necrobiosis lipoidica (diabeticorum) and its association to Miescher's granulomatosis disciformis chronica et progressiva. *Hautarzt* 1983; 34: 322-325. PMID: 6350227
63. Diasio FA. Keratosis Follicularis Sine Dyskeratosis: a Nevoid Anomaly of Development Report of a Case. *Arch Dermatol* 1932; 26: 60-67.